The bill CS/CS/HB 1617 establishes new regulations for stem cell therapy in Florida, allowing allopathic and osteopathic physicians to perform therapies that are not FDA-approved under specific conditions. It emphasizes ethical sourcing of stem cells, explicitly prohibiting the use of those derived from aborted fetuses, while promoting the use of adult stem cells and umbilical cord blood. The legislation outlines requirements for stem cells, mandating adherence to current good manufacturing practices and that they be obtained from accredited facilities. Physicians are also required to provide clear notices in advertisements about the unapproved nature of the therapies and to obtain informed consent from patients, detailing the treatment's nature and potential risks.

Furthermore, the bill includes provisions for disciplinary actions against physicians who violate these regulations and mandates the Board of Medicine and the Board of Osteopathic Medicine to adopt rules for implementation. It defines key terms related to stem cell therapy and specifies that the regulations apply to therapies related to orthopedics, wound care, or pain management. The bill does not apply to physicians with FDA approval for investigational drugs or those affiliated with accredited institutions. It is set to take effect on July 1, 2025, aiming to advance regenerative medicine in Florida while maintaining ethical standards.